Stryker stock sits at EUR 245.90, 27.1 percent below its high

Published on 10/12/2026 at 15:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stryker stock was EUR 245.90 on October 12, 2026, versus EUR 247.85 at the Xetra close. Results follow October 29, 2026.

Key points in brief

Stryker stock was EUR 245.90 at Lang & Schwarz on October 12, 2026 at 3:43 p.m. CEST.
The price was 0.79 percent below the Xetra close of October 9, 2026 at EUR 247.85.
Stryker reported USD 6.59 billion in second-quarter 2026 revenue, up 9.40 percent year over year.
Third-quarter 2026 results are scheduled for October 29, 2026.

Bauhaus-Poster mit geometrischen Formen und dem Schriftzug MEDTECH in Rot und Blau — Geometrisches Bauhaus-Poster mit Sektor-Schriftzug MEDTECH repräsentiert die Branche von Stryker Corp. US8636671013 abstrakt, Illustration mit AI erstellt.

Stryker Corp. (ISIN US8636671013) was trading at EUR 245.90 at Lang & Schwarz on October 12, 2026 at 3:43 p.m. CEST, down 0.79 percent versus the Xetra close of October 9, 2026 at EUR 247.85. The euro price places the medical-device company 27.10 percent below its 52-week high of EUR 337.30 and 16.77 percent above its 52-week low of EUR 210.60.

Price placement remains defensive

The current euro quotation is close to the lower end of the 52-week range, while the US listing provides a separate home-market reference. Stryker was last trading at USD 276.98 on the NYSE on October 12, 2026 at 9:56 a.m. ET, compared with a USD 267.00 low and a USD 392.55 high over the same 52-week period.

Trading activity was 140,711 shares at the NYSE timestamp, against an average volume of 2,620,518 shares. The gap between current volume and the average points to a quieter opening phase than the recent norm, although the session was still underway at the recorded time.

Revenue growth meets valuation pressure

Markets Insider reported on October 6, 2026 that Truist cut its Stryker price target to USD 310.00 from USD 340.00 while keeping a Hold rating. The new target lies 11.92 percent above the NYSE price of USD 276.98, giving investors a clear valuation reference without turning the comparison into a forecast.

In the second quarter of 2026, revenue reached USD 6.59 billion, an increase of 9.40 percent from the year-ago quarter, according to Simply Wall St. That operating growth contrasts with the stock's position near its yearly low and the current price-to-earnings ratio of 28.67.

Comparison with peers

Stryker Corporation: minus 0.79 percent, P/E 28.7, market capitalization USD 106.2 billion

Medtronic (NYSE, USD): plus 4.32 percent, P/E 22.6, market capitalization USD 118.1 billion

Boston Scientific (NYSE, USD): plus 0.15 percent, P/E 17.4, market capitalization USD 63.6 billion

Next results date is set

Zacks identifies October 29, 2026 as Stryker's confirmed reporting date for third-quarter 2026 results, after the US market close. Its consensus estimate is USD 3.59 for earnings per share, a periodized figure that will give the market a fresh test of the company's growth and margin execution.

Stryker stock remains below its high

Stryker stock was at EUR 245.90 at Lang & Schwarz on October 12, 2026 at 3:43 p.m. CEST, 0.79 percent below the Xetra close of October 9, 2026 at EUR 247.85. The further course of trading is shown by the continuously updated real-time quote of Stryker stock.